Pfizer Inc.
Pfizer Inc. (United States) holds 4 active US FDA Type II Drug Master Files and 62 inactive, has DMF or CEP filings on record for 40 active ingredients, holds 1 active Type IV (excipient) Drug Master File and is linked to 9 FDA-registered manufacturing sites. 50 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “Pfizer Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/pfizer-inc
Overview
Pfizer Inc. is a leading pharmaceutical company dedicated to discovering, developing, and delivering innovative medicines to improve patients' lives. Arena Pharmaceuticals, Inc., now a subsidiary of Pfizer, focuses on developing unique therapies for treating immune-inflammatory diseases.
Active ingredients with DMF or CEP filings
Substances for which Pfizer Inc. holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.
API / Drug Master Files
Pfizer Inc. holds 4 active (66 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.
- ACTIVATED CALICHEAMICIN DERIVATIVEActive2015-12-11
- PRASTERONE ACETATEActive2014-12-11
- ALPHAMETHYL EPOXIDEActive1996-09-11
- HEPARIN SODIUM USPActive1976-08-03
- CABERGOLINE USPInactive2014-12-12
- LIPITOR (ATORVASTATIN CALCIUM) 10MG, 20MG, 40MG, 80MG ORALTABLETSInactive2009-01-29
- FLUMETHASONEInactive2001-08-01
- OXYTETRACYCLINE HYDROCHLORIDEInactive1998-09-01
- CEFOPERAZONE SODIUMInactive1998-09-01
- OXYTETRACYCLINE HYDROCHLORIDEInactive1998-09-01
- TROLEANDOMYCINInactive1998-09-01
- METHACYCLINE HYDROCHLORIDEInactive1998-09-01
- OXYTETRACYCLINE HYDROCHLORIDEInactive1998-09-01
- ERYTHROMYCIN STEARATEInactive1998-09-01
- PENICILLIN V POTASSIUMInactive1998-09-01
- OXYTETRACYCLINEInactive1998-09-01
- METHACYCLINE HYDROCHLORIDEInactive1998-09-01
- DOXYCYCLINE HYCLATEInactive1998-09-01
- AMPHOTERICIN BInactive1998-09-01
- OXYTETRACYCLINE HYDROCHLORIDEInactive1998-09-01
- PENICILLIN G BENZATHINEInactive1998-09-01
- TROLEANDOMYCINInactive1998-09-01
- DOXYCYCLINE HYCLATEInactive1998-09-01
- OXYTETRACYCLINEInactive1998-09-01
- TETRACYCLINE HYDROCHLORIDEInactive1998-09-01
- CARBENICILLIN INDANYL SODIUMInactive1998-09-01
- AMPICILLIN TRIHYDRATEInactive1998-09-01
- CLINDAMYCIN HYDROCHLORIDEInactive1998-09-01
- TETRACYCLINE HYDROCHLORIDEInactive1998-09-01
- TETRACYCLINE HYDROCHLORIDEInactive1998-09-01
- PENICILLIN G SODIUMInactive1998-09-01
- DOXYCYCLINE HYCLATEInactive1998-09-01
- TETRACYCLINE HYDROCHLORIDEInactive1998-09-01
- STREPTOMYCIN SULFATEInactive1998-09-01
- PENICILLIN G PROCAINEInactive1998-09-01
- OXYTETRACYCLINE CALCIUMInactive1998-09-01
- TETRACYCLINEInactive1998-09-01
- OXYTETRACYCLINE CALCIUMInactive1998-09-01
- DOXYCYCLINE HYCLATEInactive1998-09-01
- CARBENICILLIN INDANYL SODIUMInactive1998-09-01
- TETRACYCLINEInactive1998-09-01
- TETRACYCLINEInactive1998-09-01
- PLICAMYCINInactive1998-09-01
- ERYTHROMYCINInactive1998-09-01
- VIOMYCIN SULFATEInactive1998-09-01
- PENICILLIN V POTASSIUMInactive1998-09-01
- OXYTETRACYCLINE HYDROCHLORIDEInactive1998-09-01
- HYDROXY ACIDInactive1992-07-13
- PREDNISOLONE SODIUM PHOSPHATEInactive1991-08-22
- TRIAMCINOLONE ACETONIDEInactive1990-10-31
Showing the 50 most relevant of 66 Drug Master Files (active first). The full list is in the FDA DMF list.
Excipient Drug Master Files
Pfizer Inc. holds 1 active (1 total) FDA Type IV Drug Master File. A Type IV DMF covers an excipient, colourant or flavour, not an active ingredient; these are counted separately from the API filings above.
- SULPHOBUTYLETHER BETA-CYCLODEXTRIN SODIUM (SBECD)Active1997-12-17
Registered manufacturing sites (9)
Physical sites registered with the US FDA and resolved to Pfizer Inc., with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.
- Pfizer Asia Manufacturing Pte LtdSingapore, Singapore · API manufacture
- Pfizer Health ABStrangnas, Sweden · API manufactureSite GMP match
- Pfizer IncChesterfield, United States · API manufacture
- Pfizer Ireland Pharmaceuticals Unlimited CompanyRINGASKIDDY, Ireland · API manufactureSite GMP match
- Pfizer Manufacturing Austria GmbHOrth an der Donau, Austria · API manufactureSite GMP match
- Pfizer Manufacturing Belgium NVPuurs-Sint-Amands, Belgium · Analytical testing · LabellingSite GMP match
- Pfizer Manufacturing Deutschland GmbHFreiburg im Breisgau, Germany · Analytical testing · LabellingSite GMP match
- Pharmacia & Upjohn Company LLCKalamazoo, United States · API manufacture
- Pharmacia Hepar LLCFranklin, United States · API manufacture
FDA compliance signals
50 FDA enforcement records linked to this company.
- recall — Class II2025-08-27
Lack of Assurance of Sterility.
- recall — Class II2025-08-27
Lack of Assurance of Sterility.
- recall — Class II2025-08-06
CGMP Deviations; particulates identified during visual inspection
- recall — Class II2025-08-06
CGMP Deviations; particulates identified during visual inspection
- recall — Class II2025-07-02
Discoloration; discolored solution from cracked vials
- recall — Class II2024-07-03
Lack of Assurance of Sterility-The potential for incomplete crimp seals.
- recall — Class II2024-07-03
Lack of Assurance of Sterility-The potential for incomplete crimp seals.
- recall — Class I2024-01-24
Presence of Particulate Matter; identified as glass
- recall — Class I2024-01-24
Presence of Particulate Matter; identified as glass
- recall — Class I2024-01-24
Presence of Particulate Matter; identified as glass
- recall — Class I2023-11-15
Presence of Particulate Matter: identified as glass.
- recall — Class I2023-11-15
Presence of Particulate Matter: identified as glass.
- recall — Class I2023-11-15
Presence of Particulate Matter: identified as glass.
- recall — Class III2023-04-19
Labeling: Incorrect or Missing Lot and/or Exp Date: The carton and bottle labels state an expiry date of March 2026; the correct expiration date is February 2025.
- recall — Class I2023-02-01
Presence of Particulate Matter: Glass particulate matter detected in injectable.
- recall — Class II2023-01-11
Lack of assurance of sterility: Bags have the potential to leak.
- recall — Class II2022-10-12
Presence of Particulate Matter: A complaint was received for the presence of a hair in one vial.
- recall — Class I2022-09-21
Presence of particulate matter
- recall — Class I2022-08-03
Presence of particulate matter: particulate identified as a beetle.
- recall — Class II2022-05-25
CGMP Deviations: Contains N-nitrosoquinapril above the acceptable limits.
- recall — Class II2022-05-25
CGMP Deviations: Contains N-nitrosoquinapril above the acceptable limits.
- recall — Class II2022-05-25
CGMP Deviations: Contains N-nitrosoquinapril above the acceptable limits.
- recall — Class II2022-04-13
CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.
- recall — Class II2022-04-13
CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.
- recall — Class II2022-04-13
CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.
- recall — Class II2022-04-13
CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.
- recall — Class II2022-04-13
CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.
- recall — Class II2022-04-13
CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.
- recall — Class II2022-04-13
CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.
- recall — Class II2022-04-13
CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.
- recall — Class II2021-12-08
Lack of sterility assurance: bag has the potential to leak.
- recall — Class II2021-09-29
CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit
- recall — Class II2021-09-29
CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit
- recall — Class II2021-09-29
CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit
- recall — Class II2021-09-29
CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit
- recall — Class II2021-08-11
CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDAs acceptable interim acceptable intake limit
- recall — Class II2021-08-11
CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDAs acceptable interim acceptable intake limit
- recall — Class II2021-08-11
CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit
- recall — Class I2021-06-09
Labeling: Label Mix-Up: some vials labeled to contain 0.5% Bupivacaine Hydrochloride Injection, USP may contain 1% Lidocaine HCl Injection, USP and some vials labeled to contain 1% Lidocaine HCl Injection, USP may contain 0.5% Bupivacaine Hydrochloride Injection, USP
- recall — Class I2021-06-09
Labeling: Label Mix-Up: some vials labeled to contain 0.5% Bupivacaine Hydrochloride Injection, USP may contain 1% Lidocaine HCl Injection, USP and some vials labeled to contain 1% Lidocaine HCl Injection, USP may contain 0.5% Bupivacaine Hydrochloride Injection, USP
- recall — Class II2021-05-26
Presence of Particulate Matter: particulate matter identified as an insect in one vial.
- recall — Class II2020-08-12
Lack of Assurance of Sterility; potential loose metal overseal crimp defects.
- recall — Class III2020-07-01
Failed Dissolution Specifications
- recall — Class II2020-06-17
Presence of Particulate Matter: particulate matter identified after reconstitution.
- recall — Class II2020-03-11
Lack of Assurance of Sterility--Reports of loose metal ferrule crimps on vials for injection. The entire cap either lifted or dislodged while attempting to flip off the orange color plastic button.
- recall — Class II2020-02-19
Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.
- recall — Class II2020-02-19
Defective Container: confirmed customer reports for vials with loose metal overseal crimp defects, which may result in lack of assurance of sterility.
- recall — Class II2020-02-19
Defective Container: products potentially could have been packaged in defective bottles, with a notched rim, that could cause inadequate foil sealing resulting in lack of moisture protection.
- recall — Class II2019-12-18
Labeling: Incorrect or Missing Lot and/or expiration date.
- recall — Class II2019-10-16
Lack of Assurance of Sterility: Bag has the potential to leak.
Is this Pfizer Inc.?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.